These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35054251)

  • 1. Seven-Month Analysis of Five SARS-CoV-2 Antibody Assay Results after ChAdOx1 nCoV-19 Vaccination: Significant Decrease in SARS-CoV-2 Antibody Titer.
    Jeong S; Lee N; Lee SK; Cho EJ; Hyun J; Park MJ; Song W; Jung EJ; Woo H; Seo YB; Park JJ; Kim HS
    Diagnostics (Basel); 2021 Dec; 12(1):. PubMed ID: 35054251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
    Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
    Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Results of Five SARS-CoV-2 Antibody Assays before and after the First and Second ChAdOx1 nCoV-19 Vaccinations among Health Care Workers: a Prospective Multicenter Study.
    Jeong S; Lee N; Lee SK; Cho EJ; Hyun J; Park MJ; Song W; Jung EJ; Woo H; Seo YB; Park JJ; Kim HS
    J Clin Microbiol; 2021 Nov; 59(12):e0178821. PubMed ID: 34613799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing Results of Five SARS-CoV-2 Antibody Assays Before and After the First Dose of ChAdOx1 nCoV-19 Vaccine among Health Care Workers.
    Jeong S; Lee N; Lee SK; Cho EJ; Hyun J; Park MJ; Song W; Jung EJ; Woo H; Seo YB; Park JJ; Kim HS
    J Clin Microbiol; 2021 Aug; 59(9):e0110521. PubMed ID: 34191577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies Among Vietnamese Healthcare Workers by Dosing Interval for ChAdOx1 nCoV-19 Vaccine.
    Vu DM; Vu DTB; Do TTT; Olmsted AE; Dao BH; Thai TT; Nguyen CL; Le NTT; Le TA; Bui HTT; Pham TN; Moore MR
    Clin Infect Dis; 2022 Oct; 75(Suppl 2):S174-S181. PubMed ID: 35723271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
    Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-S1/RBD-Specific Antibody Formation After SARS-CoV-2 Vaccination in Elderly Rheumatoid Arthritis Patients: Single-Center Prospective Observational Study.
    Kang ES; Oh JS; Lee EJ; Hong S; Ahn SM; Lee CK; Yoo B; Kim YG
    J Korean Med Sci; 2023 Apr; 38(14):e109. PubMed ID: 37038645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
    Jarius S; Bieber N; Haas J; Wildemann B
    J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
    Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
    Front Immunol; 2022; 13():811020. PubMed ID: 35126395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers.
    Assaid N; Arich S; Charoute H; Akarid K; Ezzikouri S; Maaroufi A; Sarih M
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose.
    Sanna G; Marongiu A; Firinu D; Piras C; Palmas V; Galdiero M; Atzori L; Caria P; Campagna M; Perra A; Costanzo G; Coghe F; Littera R; Chessa L; Manzin A
    Clin Exp Med; 2024 Jan; 24(1):12. PubMed ID: 38244064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination.
    Lee N; Jeong S; Lee SK; Cho EJ; Hyun J; Park MJ; Song W; Kim HS
    Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust specific RBD responses and neutralizing antibodies after ChAdOx1 nCoV-19 and CoronaVac vaccination in SARS-CoV-2- seropositive individuals.
    Fernandes ER; Taminato M; de Souza Apostolico J; Gabrielonni MC; Lunardelli VAS; Maricato JT; Andersen ML; Tufik S; Rosa DS
    J Allergy Clin Immunol Glob; 2023 May; 2(2):100083. PubMed ID: 36845213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults.
    Iwata S; Pollard AJ; Tada Y; Omoto S; Shibata RY; Igarashi K; Hasegawa T; Ariyasu M; Sonoyama T
    Sci Rep; 2024 Apr; 14(1):9830. PubMed ID: 38684712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variation in antibody titers determined by Abbott and Roche Elecsys SARS-CoV-2 assays in vaccinated healthcare workers.
    Nakai M; Yokoyama D; Sato T; Sato R; Kojima C; Shimosawa T
    Heliyon; 2023 Jun; 9(6):e16547. PubMed ID: 37235203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single dose ChAdOx1 nCoV-19 vaccine elicits high antibody responses in individuals with prior SARS-CoV-2 infection comparable to that of double dose vaccinated SARS-CoV-2 infection naïve individuals.
    Gelanew T; Mulu A; Abebe M; Bates TA; Wassie L; Tefer M; Fentahun D; Alemu A; Tamiru F; Assefa G; Bayih AG; Taffesse FG; Mihret A; Abdissa A
    Res Sq; 2022 Jan; ():. PubMed ID: 35043108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of SARS-CoV-2 Humoral Response Following Vaccination with ChAdOx1 nCoV-19 (Covishield™) and/or Sinopharm, BBIBP-CorV (Vero cell™).
    Kamar SB; Pandey H; Shahi R; Puri S; Yadav GK; Amgain K
    J Nepal Health Res Counc; 2024 Mar; 21(3):523-529. PubMed ID: 38615227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactogenicity and persistence of IgG antibodies against SARS-CoV-2 among recipients of ChAdOx1 nCoV-19 vaccine: A single center experience from Sri Lanka.
    Govindapala D; Dhanaratna D; Senarath U; Lamabadusuriya D; Senaratne T; Wijenayake W; Wijewardena D; Nakkawita D; Kawyangana P; Kulasekara U; Silva AD; Fernando N
    Int J Health Sci (Qassim); 2023; 17(1):36-43. PubMed ID: 36704495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
    Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
    EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.